Last reviewed 2026-06-03 · How we verify

Cyclopropylmethylscopolamine Bromide (CIMETROPIUM)

Phase 3 active Small molecule ✓ Verified Jun 2026 Quality 29/100

Cyclopropylmethylscopolamine Bromide (generic name: CIMETROPIUM) is a cimetropium drug. It is currently in Phase 3 development.

CIMETROPIUM works by blocking muscarinic receptors in the body, which are involved in various physiological processes.

Cyclopropylmethylscopolamine Bromide is a small molecule with synonyms CIMETROPIUM CATION and CIMETROPIUM ION.

Likelihood of approval

55.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CIMETROPIUM
Drug class	cimetropium
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 3

Mechanism of action

Imagine your body's nervous system as a complex network of messengers. CIMETROPIUM helps to slow down or block some of these messengers, which can help to reduce symptoms in certain conditions. This can lead to a range of effects, including relaxation of smooth muscle and decreased secretions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Usefulness Of Flospan As A Premedication For Colonoscopy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cyclopropylmethylscopolamine Bromide CI brief — competitive landscape report
Cyclopropylmethylscopolamine Bromide updates RSS · CI watch RSS

Frequently asked questions about Cyclopropylmethylscopolamine Bromide

What is Cyclopropylmethylscopolamine Bromide?

Cyclopropylmethylscopolamine Bromide (CIMETROPIUM) is a cimetropium drug.

How does Cyclopropylmethylscopolamine Bromide work?

CIMETROPIUM works by blocking muscarinic receptors in the body, which are involved in various physiological processes.

What is the generic name of Cyclopropylmethylscopolamine Bromide?

CIMETROPIUM is the generic (nonproprietary) name of Cyclopropylmethylscopolamine Bromide.

What drug class is Cyclopropylmethylscopolamine Bromide in?

Cyclopropylmethylscopolamine Bromide belongs to the cimetropium class. See all cimetropium drugs at /class/cimetropium.

What development phase is Cyclopropylmethylscopolamine Bromide in?

Cyclopropylmethylscopolamine Bromide is in Phase 3.

Drug class: All cimetropium drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing